{"meta":{"query_hash":"7626a6004b58","filters":{"venue":"Expert Opinion on Therapeutic Patents"},"cohort_total":45,"direct_labels_cover":0,"predictions_cover":45,"exported":45,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/7626a6004b58","api":"https://metacan.xera.ac/api/v1/cohort?venue=Expert+Opinion+on+Therapeutic+Patents"},"results":[{"id":"W1769059961","doi":"10.1517/13543776.2015.1086749","title":"A STAT inhibitor patent review: progress since 2011","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dairy Farmers of Ontario; University of Toronto","funders":"","keywords":"STAT5; stat; SH2 domain; Computational biology; STAT3; Cancer research; Biology; Kinase; Phosphorylation; Genetics","score_opus":0.30696338683707014,"score_gpt":0.4409019624140757,"score_spread":0.13393857557700556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1769059961","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027409074,0.99542326,0.00017195546,0.0010256103,0.0005595644,0.000013570461,0.0000878596,0.000016245589,0.002427837],"genre_scores_gemma":[0.001237662,0.9964143,0.00020219176,0.000634541,0.00032939308,0.000008962588,0.00011912171,0.0000025759064,0.0010512293],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997217,0.0000368579,0.00004015167,0.00005152254,0.00011443755,0.000035347995],"domain_scores_gemma":[0.9993799,0.00025882857,0.000121035366,0.0000119936585,0.0001855558,0.00004262145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000691614,0.0007014885,0.0010650363,0.0022023313,0.00029516165,0.0011561095,0.0007917522,0.0010117684,0.009269314],"category_scores_gemma":[0.0013199596,0.0002151469,0.00077481376,0.0025426731,0.00037631666,0.0014236614,0.00054392574,0.0016204972,0.0034216454],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009634613,0.0000470933,0.00011142545,0.022781001,0.0000830257,0.00023408125,0.000049761216,0.00021278103,0.00153698,0.0023828812,0.06096811,0.9114965],"study_design_scores_gemma":[0.00002423189,0.000097328644,0.00040239468,0.0041539287,0.00017661932,0.0008374633,0.00003969558,0.000054647,0.000603918,0.0010012495,0.9925956,0.000012930787],"about_ca_topic_score_codex":0.00078499655,"about_ca_topic_score_gemma":0.0018794709,"teacher_disagreement_score":0.009269314,"about_ca_system_score_codex":0.0006648733,"about_ca_system_score_gemma":0.0016535997,"threshold_uncertainty_score":0.031008959},"labels":[],"label_agreement":null},{"id":"W1769626824","doi":"10.1517/13543776.12.4.513","title":"Recent progress in 5-HT<sub>6</sub>receptor antagonists for the treatment of CNS diseases","year":2002,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Neurotransmitter Receptor Influence on Behavior","field":"Neuroscience","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Serotonergic; Medicine; Mechanism (biology); 5-HT6 receptor; Schizophrenia (object-oriented programming); Neuroscience; Intensive care medicine; Pharmacology; Psychiatry; 5-HT receptor; Psychology; Receptor; Serotonin; Internal medicine; Epistemology; Philosophy","score_opus":0.11949921082770117,"score_gpt":0.3431025908647595,"score_spread":0.22360338003705837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1769626824","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038577076,0.9760551,0.0020468659,0.0067204298,0.00087422563,0.000018377397,0.00004063792,0.000048510938,0.010338164],"genre_scores_gemma":[0.014830242,0.9749151,0.0023993542,0.0019087653,0.0024192142,0.000023322656,0.00008306735,0.000010357226,0.00341057],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996401,0.000104534716,0.000061482155,0.000046444944,0.000098152304,0.000049186332],"domain_scores_gemma":[0.9988939,0.00064893556,0.00013707479,0.000029618393,0.0002306761,0.000059806836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001964008,0.00051084434,0.0008485083,0.0014713642,0.00038444542,0.0013584108,0.0006004717,0.0013861716,0.007859949],"category_scores_gemma":[0.0014222844,0.0002319322,0.00046927654,0.0015622289,0.000482495,0.001955251,0.00046780938,0.0010943088,0.0022120494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068655284,0.00028136116,0.00043781515,0.010005798,0.0000914334,0.001075419,0.0002806705,0.0006445213,0.017363654,0.0097600045,0.021636672,0.9377361],"study_design_scores_gemma":[0.00014603915,0.0014558992,0.0032456953,0.0018420165,0.0004488103,0.003874529,0.00034920627,0.0005069837,0.010124398,0.0075898743,0.9703771,0.00003940082],"about_ca_topic_score_codex":0.0004938429,"about_ca_topic_score_gemma":0.0014908826,"teacher_disagreement_score":0.007859949,"about_ca_system_score_codex":0.0005503844,"about_ca_system_score_gemma":0.0009637497,"threshold_uncertainty_score":0.026294112},"labels":[],"label_agreement":null},{"id":"W1967410304","doi":"10.1517/13543776.2015.1010512","title":"Phosphorus-containing nanoparticles: biomedical patents review","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Nanotechnology; Phosphorus; Nanoparticle; Chemistry; Business; Materials science; Organic chemistry","score_opus":0.14211581921221567,"score_gpt":0.379793716350022,"score_spread":0.23767789713780635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967410304","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018513319,0.9958163,0.00014486136,0.0004633683,0.00035175757,0.000010072733,0.00004643092,0.000012612273,0.0029694713],"genre_scores_gemma":[0.0012527386,0.9964734,0.00019498575,0.00031100688,0.00026752643,0.000010080217,0.00006538715,0.0000023509122,0.0014225083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982315,0.000021145037,0.000021347512,0.000032726937,0.00008055607,0.00002111902],"domain_scores_gemma":[0.9997522,0.00009679233,0.00004890614,0.000006904337,0.000072396695,0.000022850825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004117641,0.0009049299,0.0009800022,0.00272544,0.0003114298,0.0009994883,0.0006208387,0.0010734035,0.008651671],"category_scores_gemma":[0.00060558924,0.00025470584,0.0004989138,0.0027229516,0.0003140979,0.001256131,0.0005393254,0.0011653146,0.0040729493],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044128024,0.000050541814,0.00008165749,0.01732091,0.000053784912,0.00026454832,0.000053291897,0.00024860926,0.0017867702,0.0034109107,0.047788348,0.9288966],"study_design_scores_gemma":[0.000010301196,0.000049486927,0.00027630405,0.0029749256,0.00007304946,0.0007628515,0.00003344116,0.000046628535,0.00060324714,0.0012098737,0.9939494,0.000010455477],"about_ca_topic_score_codex":0.0009945513,"about_ca_topic_score_gemma":0.0015007528,"teacher_disagreement_score":0.008651671,"about_ca_system_score_codex":0.0005685586,"about_ca_system_score_gemma":0.0011375524,"threshold_uncertainty_score":0.028942704},"labels":[],"label_agreement":null},{"id":"W1969081293","doi":"10.1517/13543776.2014.898753","title":"LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2014)","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Integrase; Allosteric regulation; Integrase inhibitor; Human immunodeficiency virus (HIV); Biology; Computational biology; Pharmacology; Virology; Enzyme; Antiretroviral therapy; Biochemistry; Viral load","score_opus":0.07985944761990504,"score_gpt":0.35796034411425753,"score_spread":0.2781008964943525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969081293","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029953846,0.9955213,0.00016512151,0.00040639617,0.00031112364,0.000021236456,0.000090473615,0.000016121536,0.003168695],"genre_scores_gemma":[0.0016385769,0.9961255,0.00020554023,0.00026055644,0.00014825333,0.0000131853385,0.0001072053,0.0000020509826,0.0014991701],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985194,0.000017145361,0.00001566702,0.00002507219,0.00006963866,0.000020592062],"domain_scores_gemma":[0.9998116,0.000068192334,0.000048695143,0.000004173886,0.000049248145,0.000018043218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036537906,0.00072543696,0.0009685858,0.0021663113,0.00022111977,0.0008018047,0.00065667,0.0008466286,0.009771365],"category_scores_gemma":[0.0005320279,0.00022477334,0.00062978227,0.0025138382,0.00026443595,0.00093202305,0.0003772004,0.0012059681,0.003681126],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008729694,0.000054189328,0.00007715163,0.019217545,0.00008358963,0.00022190835,0.000043916218,0.00025886824,0.0020061184,0.0029234763,0.041651186,0.9333747],"study_design_scores_gemma":[0.000036080604,0.0001277173,0.000566237,0.004224136,0.00015266633,0.00077393616,0.000031670883,0.000060717553,0.000594256,0.00084580184,0.99257237,0.0000145014255],"about_ca_topic_score_codex":0.0008212489,"about_ca_topic_score_gemma":0.0018336935,"teacher_disagreement_score":0.009771365,"about_ca_system_score_codex":0.0005049613,"about_ca_system_score_gemma":0.0010340525,"threshold_uncertainty_score":0.0326885},"labels":[],"label_agreement":null},{"id":"W1969226240","doi":"10.1517/13543776.12.8.1237","title":"Novel therapeutic strategies for impaired endothelium-dependent vascular relaxation","year":2002,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Eicosanoids and Hypertension Pharmacology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Endothelium; Pharmacology; Medicine; Vascular smooth muscle; Endothelial dysfunction; Angiogenesis; Fibrinolysis; Angiotensin II; Platelet; Immunology; Internal medicine; Blood pressure","score_opus":0.07753051824902753,"score_gpt":0.31534657214179657,"score_spread":0.23781605389276905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969226240","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09006356,0.7340517,0.06441086,0.03498547,0.005418837,0.000858465,0.00051655405,0.0006750106,0.06901963],"genre_scores_gemma":[0.38459802,0.53328645,0.03612232,0.009691197,0.0038856266,0.0010502194,0.0007407023,0.00008506861,0.030540409],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998344,0.000051202198,0.000009078784,0.000025848232,0.000033186112,0.000046314806],"domain_scores_gemma":[0.999907,0.00003193332,0.0000161055,0.000008358219,0.000018460396,0.000018089188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064530317,0.00053526676,0.00082301354,0.0005609374,0.00028977572,0.0008950504,0.00083250104,0.0010635346,0.008504436],"category_scores_gemma":[0.000292269,0.00013438055,0.00051021023,0.0002839686,0.00055823673,0.0008278157,0.0005060903,0.0017299752,0.0016026846],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018559026,0.0019351004,0.0006844166,0.0037153552,0.000192415,0.0028909454,0.00034548203,0.0015031749,0.19115151,0.07042166,0.025115939,0.700188],"study_design_scores_gemma":[0.0027374793,0.007596969,0.005088219,0.0014662953,0.0005200402,0.0083573805,0.0005227913,0.0038021982,0.08223652,0.053347953,0.8342037,0.000120576035],"about_ca_topic_score_codex":0.00022185425,"about_ca_topic_score_gemma":0.00052692264,"teacher_disagreement_score":0.008504436,"about_ca_system_score_codex":0.00038169976,"about_ca_system_score_gemma":0.0003937319,"threshold_uncertainty_score":0.028450191},"labels":[],"label_agreement":null},{"id":"W1982970232","doi":"10.1517/13543776.2013.780598","title":"Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005 – 2013)","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Enzyme function and inhibition","field":"Biochemistry, Genetics and Molecular Biology","cited_by":295,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Carbonic anhydrase; Pharmacology; Chlorthalidone; Chemistry; Furosemide; Diuretic; Hydrochlorothiazide; Bumetanide; Drug; Acetazolamide; Medicine; Internal medicine; Blood pressure; Enzyme; Biochemistry","score_opus":0.0921937601477758,"score_gpt":0.33820708731809257,"score_spread":0.24601332717031676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982970232","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00082102633,0.9939382,0.0001668091,0.0010084297,0.00023947888,0.000027515694,0.00042310075,0.000016032092,0.0033594107],"genre_scores_gemma":[0.0036414652,0.99437463,0.00020061951,0.0005436818,0.00022549849,0.000016696646,0.0003416036,0.000002846368,0.000652883],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995493,0.00004931662,0.000102431695,0.00007793893,0.0001754086,0.000045486096],"domain_scores_gemma":[0.99877876,0.0005365248,0.00035019123,0.000017078077,0.0002724865,0.00004494649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007130454,0.0007116921,0.0011418201,0.00506135,0.0003020882,0.0011627149,0.0007834892,0.0009886794,0.015560569],"category_scores_gemma":[0.002198308,0.00022802221,0.0011660462,0.0057461504,0.00035794184,0.0014330511,0.00050833914,0.00089411036,0.0025689064],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002368378,0.00007657108,0.0008137757,0.08831286,0.00026386746,0.00086317054,0.00016135817,0.0002551666,0.0015393051,0.0028498475,0.053345855,0.8512814],"study_design_scores_gemma":[0.00007080895,0.00024581468,0.0056700227,0.040336363,0.001529859,0.0042660786,0.00019938144,0.0001631599,0.0009546222,0.0016293607,0.94488823,0.00004629336],"about_ca_topic_score_codex":0.0014680834,"about_ca_topic_score_gemma":0.0022393654,"teacher_disagreement_score":0.015560569,"about_ca_system_score_codex":0.0007596372,"about_ca_system_score_gemma":0.0019818537,"threshold_uncertainty_score":0.0520553},"labels":[],"label_agreement":null},{"id":"W1989556851","doi":"10.1517/13543770903059125","title":"The search for new COX-2 inhibitors: a review of 2002 – 2008 patents","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundação de Amparo à Pesquisa do Estado de Minas Gerais; Merck Canada; Conselho Nacional de Desenvolvimento Científico e Tecnológico","keywords":"Naproxen; Valdecoxib; Celecoxib; Medicine; Ibuprofen; Pharmacology; Inflammation; Cyclooxygenase; Nabumetone; Aspirin; Etoricoxib; Nonsteroidal; Chemistry; Enzyme; Rofecoxib; Internal medicine; Biochemistry","score_opus":0.13245205505203045,"score_gpt":0.4087917491154659,"score_spread":0.27633969406343545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989556851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032454828,0.99688077,0.000107099,0.00041186417,0.00023073475,0.000013669571,0.000048196154,0.000008069278,0.0019750136],"genre_scores_gemma":[0.001033253,0.9971239,0.00025554645,0.00032390998,0.00023156176,0.000010292571,0.00009153367,0.0000014568361,0.00092855416],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997639,0.000030644613,0.00003551642,0.000036115893,0.00011271755,0.000021127033],"domain_scores_gemma":[0.99964976,0.000108689484,0.00009148942,0.0000074599843,0.00010920827,0.000033366123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056544435,0.000990247,0.001415107,0.004051274,0.00027843923,0.0008630234,0.0008635869,0.0008962286,0.007669982],"category_scores_gemma":[0.00086088997,0.00031768772,0.0006458634,0.0046129297,0.00026767465,0.0014459547,0.0004371291,0.0008794495,0.002801797],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000117567615,0.0000835235,0.00015606551,0.023358893,0.00012990994,0.0005179402,0.00006380517,0.00033638134,0.0021119397,0.0015681731,0.05024028,0.9213155],"study_design_scores_gemma":[0.000068495276,0.00019289926,0.0012490939,0.0066406834,0.0003119779,0.0017310319,0.000071206974,0.00012154372,0.00069221825,0.0009618573,0.9879382,0.000020740996],"about_ca_topic_score_codex":0.0010159038,"about_ca_topic_score_gemma":0.002930473,"teacher_disagreement_score":0.007669982,"about_ca_system_score_codex":0.0008698654,"about_ca_system_score_gemma":0.0012546333,"threshold_uncertainty_score":0.025658667},"labels":[],"label_agreement":null},{"id":"W1993341051","doi":"10.1517/13543776.12.12.1795","title":"Developments in mitogen-induced extracellular kinase 1 inhibitors and their use in the treatment of disease","year":2002,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital; University of Toronto","funders":"","keywords":"MAPK/ERK pathway; Kinase; Signal transduction; Cancer research; Extracellular; Protein kinase A; Mitogen-activated protein kinase; Immune system; ASK1; Biology; Cell biology; Medicine; Immunology; Mitogen-activated protein kinase kinase","score_opus":0.08536307861861339,"score_gpt":0.27448759424772895,"score_spread":0.18912451562911556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993341051","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014300221,0.94331086,0.007727202,0.008023686,0.0014236999,0.00010466212,0.00009344928,0.000103040955,0.024913149],"genre_scores_gemma":[0.08469233,0.8829606,0.011015098,0.004334831,0.003059758,0.00019634052,0.00021288959,0.000031885706,0.013496347],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99973875,0.00008220606,0.000020197516,0.000035733636,0.00008392109,0.0000392901],"domain_scores_gemma":[0.9997248,0.00013904498,0.000040368188,0.000014062248,0.000050313338,0.000031382697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011941828,0.00061758194,0.00083230063,0.00094062736,0.00025863913,0.000806969,0.00060291355,0.0012507912,0.0035570087],"category_scores_gemma":[0.00050958036,0.00019366949,0.00044376912,0.0006286956,0.00057464046,0.0009399636,0.00039033752,0.0019682467,0.0017337252],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008208301,0.0006001319,0.000485331,0.002344545,0.000081732855,0.0012457658,0.00013953344,0.00085457246,0.054280914,0.016967217,0.014295707,0.90788376],"study_design_scores_gemma":[0.00076100783,0.0027133792,0.0026322324,0.0004896488,0.0001466248,0.005042769,0.00007140132,0.0008878004,0.030434951,0.008049482,0.9487237,0.000047137342],"about_ca_topic_score_codex":0.00037868755,"about_ca_topic_score_gemma":0.0009935867,"teacher_disagreement_score":0.0035570087,"about_ca_system_score_codex":0.00051016745,"about_ca_system_score_gemma":0.0004758575,"threshold_uncertainty_score":0.011899352},"labels":[],"label_agreement":null},{"id":"W2006746802","doi":"10.1517/13543776.2010.505604","title":"17β-Hydroxysteroid dehydrogenase inhibitors: a patent review","year":2010,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Dehydrogenase; Hydroxysteroid dehydrogenase; Chemistry; Biochemistry; Enzyme; Pharmacology; Biology","score_opus":0.07400655074951908,"score_gpt":0.35291488047837893,"score_spread":0.27890832972885987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006746802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00054033945,0.981977,0.0006523814,0.005817413,0.0024564248,0.00003857649,0.00020420531,0.00004720355,0.008266453],"genre_scores_gemma":[0.0024542285,0.98968303,0.00051777967,0.002190014,0.0011422107,0.000032721513,0.0001985458,0.00000806159,0.0037734658],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997223,0.00004063758,0.000027337475,0.000043680582,0.00013112368,0.000034958062],"domain_scores_gemma":[0.9994246,0.00022090082,0.00011594277,0.000013761738,0.00017325729,0.00005162771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006941305,0.0005889365,0.0008844887,0.001317432,0.00026527277,0.0013670314,0.00073578284,0.001463317,0.013412591],"category_scores_gemma":[0.0014102276,0.00018177323,0.0007315302,0.0017226721,0.00029358632,0.0015649855,0.0004716091,0.0017372121,0.005054986],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010080736,0.000071226576,0.00011669761,0.012382902,0.00007907066,0.00038274768,0.000055437835,0.00023048092,0.0015021284,0.0051351846,0.13690351,0.8430398],"study_design_scores_gemma":[0.000021975226,0.00007425351,0.00024895102,0.0028508112,0.00010506474,0.00055444986,0.000026453341,0.000056401776,0.000293119,0.0017317531,0.9940276,0.000009173314],"about_ca_topic_score_codex":0.0005827989,"about_ca_topic_score_gemma":0.0010978956,"teacher_disagreement_score":0.013412591,"about_ca_system_score_codex":0.00056560227,"about_ca_system_score_gemma":0.0015765241,"threshold_uncertainty_score":0.0448696},"labels":[],"label_agreement":null},{"id":"W2010505546","doi":"10.1517/13543776.2011.593510","title":"Cyclooxygenase-2 inhibitors: a literature and patent review (2009 – 2010)","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Alberta","funders":"","keywords":"Cyclooxygenase; Chemistry; Pharmacology; Medicine; Biochemistry; Enzyme","score_opus":0.1377688192194239,"score_gpt":0.3557674840241276,"score_spread":0.2179986648047037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010505546","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00067006296,0.991017,0.00022475678,0.0017990165,0.0008607242,0.000033376982,0.00042166942,0.000025211288,0.004948213],"genre_scores_gemma":[0.0031368178,0.99212766,0.0002817755,0.0010944738,0.00070998515,0.00001995295,0.0005380578,0.0000041121007,0.002087056],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999765,0.000028856339,0.00003158224,0.00003835428,0.000104847815,0.000031349828],"domain_scores_gemma":[0.9995332,0.00009334138,0.00012932536,0.000009831018,0.000197258,0.000037182144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043395426,0.00071082317,0.0010983616,0.0030572717,0.0002282778,0.00081480906,0.00078952324,0.0009433333,0.017042696],"category_scores_gemma":[0.0009311239,0.00019705927,0.0008274103,0.003548236,0.0002317297,0.0010966345,0.00042868734,0.0009756883,0.0060173585],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014989341,0.00006661383,0.00019830058,0.021528447,0.000119633165,0.00038388598,0.000040156716,0.00019665385,0.0018237672,0.0009920535,0.10485661,0.8696439],"study_design_scores_gemma":[0.00007395479,0.00020383968,0.002552178,0.011106865,0.00049999723,0.0022671304,0.000056693265,0.0001176206,0.00090820325,0.00080553826,0.98138225,0.00002575113],"about_ca_topic_score_codex":0.0009703264,"about_ca_topic_score_gemma":0.0024883635,"teacher_disagreement_score":0.017042696,"about_ca_system_score_codex":0.00055923767,"about_ca_system_score_gemma":0.0015050548,"threshold_uncertainty_score":0.05701351},"labels":[],"label_agreement":null},{"id":"W2013882224","doi":"10.1517/13543770802554275","title":"Recently patented agents with possible antipsychotic indication","year":2008,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Antipsychotic; Agonism; Medicine; Mechanism (biology); Pharmacology; Atypical antipsychotic; Pharmacodynamics; Antagonism; Mechanism of action; Psychiatry; Receptor; Schizophrenia (object-oriented programming); Biology; Internal medicine; Political science; Pharmacokinetics","score_opus":0.12288572048776221,"score_gpt":0.35694285539525683,"score_spread":0.23405713490749464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013882224","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0072313976,0.9591113,0.0010877106,0.002637093,0.0005232827,0.00014620877,0.0015095996,0.000043621636,0.027709786],"genre_scores_gemma":[0.071050555,0.9122425,0.0050958223,0.0025260467,0.001198439,0.00013253189,0.0018467949,0.0000144552305,0.0058928286],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990165,0.00016243961,0.00021236285,0.00009694126,0.00044079506,0.00007099492],"domain_scores_gemma":[0.9965643,0.0016805117,0.00095656107,0.000078968646,0.0006527097,0.00006698647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015852577,0.00042217394,0.0009122546,0.0054090237,0.00047761796,0.0016436052,0.0008861776,0.001099677,0.016883804],"category_scores_gemma":[0.0049222535,0.00013323134,0.00127682,0.0063459836,0.00057511195,0.0015385748,0.00040954753,0.0006869111,0.0015109363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008025883,0.00012459209,0.0044156336,0.08373369,0.0007767614,0.0074642664,0.00043220498,0.00035894773,0.011007709,0.0126990825,0.040307403,0.83787704],"study_design_scores_gemma":[0.00034206602,0.00041516498,0.0111457305,0.023716174,0.003980302,0.011842372,0.00033893486,0.00027562134,0.007997365,0.004793936,0.935088,0.00006423945],"about_ca_topic_score_codex":0.005254199,"about_ca_topic_score_gemma":0.011533699,"teacher_disagreement_score":0.016883804,"about_ca_system_score_codex":0.002397739,"about_ca_system_score_gemma":0.0048939134,"threshold_uncertainty_score":0.056481898},"labels":[],"label_agreement":null},{"id":"W2018494913","doi":"10.1517/13543776.2014.851669","title":"An overview of patented small molecule stearoyl coenzyme-A desaturase inhibitors (2009 – 2013)","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aboriginal Affairs Northern Dev Canada","funders":"Glenmark Pharmaceuticals; Pfizer","keywords":"Adverse effect; Pharmacology; Medicine; Small molecule; Fatty liver; Bioinformatics; Biology; Cancer research; Biochemistry; Internal medicine","score_opus":0.27537770642034,"score_gpt":0.4409548434803954,"score_spread":0.1655771370600554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018494913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031303192,0.9946025,0.00028908232,0.0004156399,0.00031706516,0.00002988671,0.00010421712,0.000022111602,0.003906488],"genre_scores_gemma":[0.0011790335,0.99606293,0.00038359492,0.00031185214,0.00014746876,0.000022979746,0.00012172538,0.0000030093752,0.0017672741],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997991,0.00002476815,0.0000333392,0.00004124564,0.00008032644,0.000021172253],"domain_scores_gemma":[0.9997179,0.00010601876,0.00005902774,0.0000066660837,0.00008488305,0.000025599375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005079265,0.0010041259,0.0011988162,0.0035322255,0.00030992334,0.0008779583,0.0008406542,0.001061845,0.0091465255],"category_scores_gemma":[0.0006982171,0.00034923528,0.0007623215,0.0027902883,0.00030767443,0.0013623748,0.0005732108,0.0015940517,0.0045193937],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075642914,0.000103921164,0.00010201957,0.019447103,0.00006688273,0.00025613376,0.000050233204,0.00024982158,0.0027508102,0.002380462,0.031007843,0.94350904],"study_design_scores_gemma":[0.000029572124,0.00017392657,0.000694957,0.004604161,0.0001266881,0.0012339894,0.00004132852,0.00010100282,0.00092518405,0.0008274917,0.9912232,0.000018533738],"about_ca_topic_score_codex":0.0010529106,"about_ca_topic_score_gemma":0.0022508276,"teacher_disagreement_score":0.0091465255,"about_ca_system_score_codex":0.00068203016,"about_ca_system_score_gemma":0.000920732,"threshold_uncertainty_score":0.030598104},"labels":[],"label_agreement":null},{"id":"W2020008986","doi":"10.1517/13543776.12.8.1215","title":"Gangliosides: therapeutic agents or therapeutic targets?","year":2002,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Neurodegeneration; Drug; Computational biology; Glycolipid; Drug discovery; Biology; Neuroscience; Pharmacology; Medicine; Immunology; Bioinformatics; Disease","score_opus":0.11059924822502899,"score_gpt":0.3483887617806951,"score_spread":0.23778951355566613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020008986","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039936174,0.9456298,0.00250947,0.029666128,0.0023513737,0.000045090514,0.00009155502,0.000055847242,0.015657222],"genre_scores_gemma":[0.040530324,0.92882514,0.0029732264,0.009201131,0.0036688545,0.000104735795,0.00012838177,0.000022878245,0.014545321],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99968326,0.000097991,0.000025401603,0.00004537066,0.00009619021,0.000051843836],"domain_scores_gemma":[0.9998449,0.000045817193,0.000029024997,0.000014179907,0.00003754327,0.000028427252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008950769,0.0006702604,0.0012962074,0.00069342204,0.00035607218,0.0016884315,0.00065078645,0.0021490057,0.0063219955],"category_scores_gemma":[0.00052074506,0.00016026286,0.00022308345,0.0006832184,0.0015642985,0.003275491,0.00072297,0.0017115485,0.0031243507],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065598753,0.00019396131,0.00057607284,0.004549636,0.000067345725,0.0013880887,0.00024352063,0.0004058242,0.035754368,0.13854702,0.05638076,0.7612373],"study_design_scores_gemma":[0.0001461351,0.00037796778,0.00039993064,0.0008421493,0.00007320415,0.0028357059,0.0003478829,0.00022532839,0.011024646,0.05156966,0.9321269,0.000030477844],"about_ca_topic_score_codex":0.00038986336,"about_ca_topic_score_gemma":0.0006918916,"teacher_disagreement_score":0.0063219955,"about_ca_system_score_codex":0.0010728268,"about_ca_system_score_gemma":0.00085167756,"threshold_uncertainty_score":0.021149158},"labels":[],"label_agreement":null},{"id":"W2020159664","doi":"10.1517/13543776.2010.533171","title":"Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature","year":2010,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Natural Antidiabetic Agents Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Calgary; F. Hoffmann-La Roche","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Macrovascular disease; Insulin resistance; Glycemic; Insulin; Disease; Diabetic retinopathy; Nephropathy; Retinopathy; Obesity; Internal medicine; Endocrinology; Intensive care medicine","score_opus":0.161926584440197,"score_gpt":0.38115649454428646,"score_spread":0.21922991010408946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020159664","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017379664,0.98190916,0.00023931958,0.0018906081,0.00049756287,0.00009883294,0.0018200094,0.000040921674,0.0117657],"genre_scores_gemma":[0.008979228,0.98292625,0.0004730092,0.0013459771,0.00052777596,0.000104998486,0.0015519323,0.000014033028,0.004076838],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989287,0.0001498916,0.00017786457,0.00011961802,0.000524672,0.00009916814],"domain_scores_gemma":[0.99739313,0.0009424364,0.0008458304,0.00003530574,0.0006600694,0.00012317802],"candidate_categories":["bibliometrics"],"consensus_categories":[],"category_scores_codex":[0.0011090232,0.00068846764,0.0009973305,0.008859657,0.00031032693,0.0015179204,0.0007281955,0.0008252941,0.018511318],"category_scores_gemma":[0.0033347923,0.00018733939,0.0012993922,0.013803275,0.00022702626,0.0013062336,0.0006345511,0.00067423325,0.0039255465],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021184147,0.00010397714,0.0009660734,0.032445848,0.00018623087,0.00026704086,0.00008022618,0.00013018343,0.000958837,0.0013688761,0.103322774,0.85995805],"study_design_scores_gemma":[0.000082306295,0.00026754843,0.009446633,0.022089478,0.0008861782,0.0011438556,0.00020525057,0.00010247238,0.00082663936,0.00047010696,0.96445215,0.000027403801],"about_ca_topic_score_codex":0.0017945623,"about_ca_topic_score_gemma":0.0033280016,"teacher_disagreement_score":0.99114037,"about_ca_system_score_codex":0.0011672359,"about_ca_system_score_gemma":0.0023676148,"threshold_uncertainty_score":0.061926544},"labels":[],"label_agreement":null},{"id":"W2027041011","doi":"10.1517/13543776.17.3.277","title":"Therapeutic advances in the treatment of osteoporosis","year":2007,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Bone health and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Osteoporosis; Medicine; Strontium ranelate; Anabolic Agents; Bisphosphonate; Teriparatide; Pharmacology; Intensive care medicine; Internal medicine; Bone mineral","score_opus":0.0757609616107818,"score_gpt":0.38584861331014875,"score_spread":0.3100876516993669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027041011","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015080688,0.97243166,0.0018017894,0.008314467,0.0011105585,0.00003479999,0.00007299968,0.00003562212,0.014690084],"genre_scores_gemma":[0.016113026,0.9697121,0.003339701,0.0030661013,0.0024202315,0.00004727495,0.00011306114,0.000009893325,0.005178652],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99952555,0.00011704596,0.000037517788,0.0000641846,0.00021430705,0.00004131544],"domain_scores_gemma":[0.999587,0.00015952344,0.00006704191,0.000022760016,0.00012155686,0.000042069147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010761059,0.00057702983,0.0008198771,0.0013254061,0.00038883614,0.0009329448,0.0006366516,0.001258088,0.013389315],"category_scores_gemma":[0.0010859997,0.00014099301,0.0006144406,0.0010983857,0.0005497469,0.0009583648,0.00064690056,0.0021297156,0.0032819721],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002751546,0.0003131448,0.00033966659,0.0044975104,0.000097982134,0.00064881827,0.00009773184,0.00036588553,0.0075068325,0.016353944,0.032621365,0.93688196],"study_design_scores_gemma":[0.000205621,0.0005775843,0.0013272227,0.0013471672,0.00015615413,0.0020100998,0.00007442599,0.0002530202,0.0024741571,0.010053101,0.98149705,0.00002447684],"about_ca_topic_score_codex":0.00067802373,"about_ca_topic_score_gemma":0.0014880367,"teacher_disagreement_score":0.013389315,"about_ca_system_score_codex":0.00059334724,"about_ca_system_score_gemma":0.0009925574,"threshold_uncertainty_score":0.044791758},"labels":[],"label_agreement":null},{"id":"W2031439958","doi":"10.1517/13543776.11.4.625","title":"Novel serotonergic and non-serotonergic migraine headache therapies","year":2001,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"IDELIX Software (Canada)","funders":"","keywords":"Sumatriptan; Migraine; Rizatriptan; Zolmitriptan; Triptans; Medicine; Serotonergic; Pharmacology; Methysergide; Intensive care medicine; Neuroscience; Serotonin; Psychology; Agonist; Anesthesia; Internal medicine; Receptor","score_opus":0.0809376976532069,"score_gpt":0.3430766452850072,"score_spread":0.2621389476318003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031439958","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046571564,0.8949942,0.006032902,0.002797386,0.0014724699,0.00022110096,0.00065680454,0.00016265364,0.0470909],"genre_scores_gemma":[0.16340657,0.7861785,0.008588162,0.0026941497,0.0025516504,0.0002572968,0.0009456714,0.000020251244,0.035357766],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998821,0.000013803903,0.000008480738,0.000020777523,0.000050053895,0.000024805144],"domain_scores_gemma":[0.9999486,0.000011726128,0.000012481017,0.0000027200397,0.000013870118,0.000010644878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026999143,0.00044949516,0.00054149295,0.00088130333,0.0002301095,0.0006034249,0.0004338614,0.00054182124,0.008317623],"category_scores_gemma":[0.0001781702,0.000103251776,0.00039436822,0.0003939429,0.00021440127,0.0006138038,0.0003310535,0.0006268895,0.0017122485],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005803486,0.00055628177,0.0004286086,0.0042056898,0.000075913515,0.0014490435,0.00013982967,0.0006351068,0.09345236,0.014596559,0.011574569,0.8723057],"study_design_scores_gemma":[0.00063754193,0.0056990287,0.008889639,0.0015958183,0.0003232523,0.009507434,0.00015146573,0.0015991189,0.06089048,0.008708934,0.90193164,0.000065692235],"about_ca_topic_score_codex":0.00022981656,"about_ca_topic_score_gemma":0.0007972372,"teacher_disagreement_score":0.008317623,"about_ca_system_score_codex":0.0004097774,"about_ca_system_score_gemma":0.00023443358,"threshold_uncertainty_score":0.027825236},"labels":[],"label_agreement":null},{"id":"W2067881291","doi":"10.1517/13543776.2013.736494","title":"Tanshinone derivatives: a patent review (January 2006 – September 2012)","year":2012,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Traditional Chinese Medicine Analysis","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Neuroprotection; Prodrug; Pharmacology; In vivo; Chemistry; Kinase; Medicine; Biochemistry; Biology","score_opus":0.30002122565777783,"score_gpt":0.41776020492084603,"score_spread":0.1177389792630682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067881291","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00089559215,0.99124056,0.00029167256,0.0005182759,0.00053246727,0.000041092335,0.00014333404,0.000027397999,0.0063095703],"genre_scores_gemma":[0.0039212895,0.99079764,0.00045402264,0.00040527695,0.00026936698,0.0000284312,0.00020500472,0.0000037151517,0.003915176],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998747,0.0000111290055,0.000015347148,0.000022331247,0.00005863419,0.000017832674],"domain_scores_gemma":[0.99987805,0.000031384516,0.000030724987,0.0000037820557,0.000040360286,0.000015661242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002826322,0.0009943472,0.0009941781,0.0025571464,0.0003072983,0.00078522996,0.000621272,0.00075534196,0.011543395],"category_scores_gemma":[0.00039901715,0.00024613005,0.0005521262,0.002967883,0.0002682201,0.0011468438,0.0004590321,0.000972511,0.0047966507],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008586171,0.00008173323,0.00010450101,0.013286276,0.000065701366,0.0005153019,0.000049849154,0.00023162286,0.0035336092,0.0019252389,0.034516383,0.9456038],"study_design_scores_gemma":[0.00004464655,0.00014015814,0.0008400127,0.0021795856,0.00014588199,0.0014567131,0.000042770283,0.00007021899,0.0012242656,0.0007071876,0.9931312,0.000017397102],"about_ca_topic_score_codex":0.0010348354,"about_ca_topic_score_gemma":0.0022948168,"teacher_disagreement_score":0.011543395,"about_ca_system_score_codex":0.00053973706,"about_ca_system_score_gemma":0.0010623721,"threshold_uncertainty_score":0.03861648},"labels":[],"label_agreement":null},{"id":"W2068430448","doi":"10.1517/13543770802672598","title":"Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Hepatitis C virus research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Hepatitis C virus; Medicine; Cirrhosis; Disease; Virus; Liver disease; Hepatitis C; Immunology; Intensive care medicine; Virology; Internal medicine","score_opus":0.19760100309243278,"score_gpt":0.45642617193886964,"score_spread":0.25882516884643686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068430448","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035618775,0.9965076,0.00021584911,0.00043177794,0.0002801237,0.00001045537,0.000016250044,0.000011253169,0.0021705776],"genre_scores_gemma":[0.001364953,0.997118,0.00033687855,0.0002412557,0.0002881439,0.000007702862,0.000028784385,0.0000012990872,0.00061294035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975234,0.000045937726,0.000034607558,0.000034497698,0.00010531287,0.00002734625],"domain_scores_gemma":[0.9995259,0.00020580292,0.000076020544,0.000013012219,0.00013996821,0.000039305527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001073767,0.0008096228,0.0010597248,0.002219055,0.0002512409,0.00079157186,0.0007765464,0.0008883926,0.004637915],"category_scores_gemma":[0.00097622245,0.00022280966,0.0005370703,0.0023471084,0.00037363602,0.0012449868,0.00041788802,0.0010762038,0.0024292148],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013696858,0.000096242424,0.00016325206,0.015204219,0.00009450061,0.00041422356,0.000073055555,0.0005016509,0.0039895657,0.0026424674,0.024735086,0.9519487],"study_design_scores_gemma":[0.00007133832,0.00031000396,0.0010235825,0.0029276013,0.00020550736,0.0018058056,0.00006414717,0.00021077805,0.0017716542,0.001694912,0.98989165,0.000022901319],"about_ca_topic_score_codex":0.00069625914,"about_ca_topic_score_gemma":0.0014244661,"teacher_disagreement_score":0.004637915,"about_ca_system_score_codex":0.00056313485,"about_ca_system_score_gemma":0.00097657,"threshold_uncertainty_score":0.015515387},"labels":[],"label_agreement":null},{"id":"W2069045375","doi":"10.1517/13543776.2011.539205","title":"Signal transducer and activator of transcription 3 inhibitors: a patent review","year":2010,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"STAT protein; STAT3; Regulator; In vivo; Computational biology; Small molecule; Peptidomimetic; Medicine; Cancer research; stat; Biology; Pharmacology; Signal transduction; Cell biology; Peptide; Biochemistry; Gene; Genetics","score_opus":0.18644807911706654,"score_gpt":0.39049153745478055,"score_spread":0.204043458337714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069045375","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008693007,0.98195124,0.00072397594,0.0024064835,0.0013500437,0.00006236864,0.00017509662,0.000046043184,0.012415516],"genre_scores_gemma":[0.0024546064,0.9882457,0.00096606574,0.0012420237,0.00067560666,0.000044662946,0.00022195355,0.000005854365,0.006143569],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998528,0.000015359637,0.000011959932,0.000022687218,0.00007688825,0.000020355472],"domain_scores_gemma":[0.9998616,0.00004377888,0.000029268396,0.000004444716,0.000042728338,0.000018190085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037939232,0.0009476376,0.0010840596,0.0016074046,0.00029443426,0.0008985359,0.00071585673,0.0011294317,0.009235233],"category_scores_gemma":[0.00044436657,0.00021541494,0.0005064517,0.0021208036,0.0002797772,0.0012213378,0.00038653586,0.0016176698,0.0058469055],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008363215,0.0001408448,0.0000646412,0.004676812,0.000040532523,0.00043159508,0.000031724692,0.00031633364,0.0035226792,0.0040069288,0.07614659,0.91053766],"study_design_scores_gemma":[0.00005527988,0.00014194686,0.00040636008,0.0013044648,0.00005864876,0.0010614203,0.000021256352,0.00010360057,0.0006800466,0.00144378,0.9947108,0.000012383405],"about_ca_topic_score_codex":0.0008023798,"about_ca_topic_score_gemma":0.0017206675,"teacher_disagreement_score":0.009235233,"about_ca_system_score_codex":0.00064230466,"about_ca_system_score_gemma":0.0010987619,"threshold_uncertainty_score":0.030894935},"labels":[],"label_agreement":null},{"id":"W2084903264","doi":"10.1517/13543776.17.4.371","title":"Metabotropic glutamate receptor 5 modulators and their potential therapeutic applications","year":2007,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Neuroscience and Neuropharmacology Research","field":"Neuroscience","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"AstraZeneca","keywords":"Metabotropic glutamate receptor; Metabotropic glutamate receptor 5; Neuroscience; Metabotropic receptor; Metabotropic glutamate receptor 2; Glutamate receptor; Receptor; Class C GPCR; Metabotropic glutamate receptor 1; Metabotropic glutamate receptor 7; Pharmacology; Biology; Biochemistry","score_opus":0.08032992125195253,"score_gpt":0.3618215717416292,"score_spread":0.28149165048967667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084903264","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004042969,0.9767402,0.0014135808,0.002963979,0.0008518746,0.000045780933,0.00021960204,0.00006899016,0.013653053],"genre_scores_gemma":[0.03666609,0.94575197,0.0026089742,0.003271958,0.0011737257,0.000095221534,0.00047784852,0.00001173523,0.009942451],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985874,0.000028457836,0.000012910268,0.000022390108,0.000049450395,0.000028098651],"domain_scores_gemma":[0.99990463,0.000021126823,0.000026471997,0.0000035081523,0.000028847382,0.000015463436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004347198,0.00049498054,0.0006161994,0.00087596546,0.00018027089,0.0007142601,0.0005483721,0.0009950295,0.008578535],"category_scores_gemma":[0.00041772632,0.00012843354,0.00056369364,0.00055764057,0.00023433413,0.000566533,0.00042673433,0.0014962715,0.002499495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054834154,0.0003151504,0.00034679475,0.0054959594,0.0001038388,0.000812438,0.000114804316,0.00061260245,0.020980235,0.016393788,0.03507631,0.9191997],"study_design_scores_gemma":[0.00017370757,0.0012106153,0.0013349052,0.0015205087,0.00012233433,0.0017172353,0.00006625557,0.00040852613,0.0049953195,0.0053645517,0.9830555,0.000030631225],"about_ca_topic_score_codex":0.00036563343,"about_ca_topic_score_gemma":0.0012205691,"teacher_disagreement_score":0.008578535,"about_ca_system_score_codex":0.00042710386,"about_ca_system_score_gemma":0.00035167573,"threshold_uncertainty_score":0.028698087},"labels":[],"label_agreement":null},{"id":"W2102449842","doi":"10.1517/13543776.10.5.675","title":"Tyrosine phosphatases: cellular functions and therapeutic potential","year":2000,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Protein Tyrosine Phosphatases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada)","funders":"","keywords":"Protein tyrosine phosphatase; Tyrosine; Tyrosine phosphorylation; Receptor tyrosine kinase; Phosphorylation; Protein phosphorylation; Biochemistry; Tyrosine kinase; SH2 domain; Platelet-derived growth factor receptor; Cell biology; Proto-oncogene tyrosine-protein kinase Src; Phosphatase; Chemistry; Biology; Signal transduction; Protein kinase A; Receptor; Growth factor","score_opus":0.0197475529811363,"score_gpt":0.2656236591770438,"score_spread":0.2458761061959075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102449842","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042022793,0.98363566,0.0013957826,0.0039036602,0.00046578268,0.000012228536,0.00006665253,0.00003666663,0.006281339],"genre_scores_gemma":[0.053793225,0.93672806,0.0018324952,0.0011959648,0.0009920808,0.000039122802,0.00013787286,0.000009585883,0.0052716457],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997819,0.00004398798,0.000014937781,0.000033946795,0.000086183194,0.00003912413],"domain_scores_gemma":[0.99985445,0.000042270734,0.000028380742,0.000010266597,0.000034332417,0.000030286465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075665815,0.00064187136,0.00078791403,0.0006519501,0.00031731543,0.0013959975,0.00045435576,0.0011433831,0.0037139442],"category_scores_gemma":[0.0005526967,0.00015413128,0.00033674776,0.00071607507,0.0007193273,0.001153459,0.00059999374,0.001821751,0.0016465645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006111116,0.0001626523,0.0005974208,0.0037472055,0.00008493247,0.0013114822,0.00013501798,0.0008967809,0.075211495,0.038010247,0.02511998,0.85411155],"study_design_scores_gemma":[0.0001762178,0.000683601,0.0016734505,0.0006602794,0.00016016515,0.006677677,0.00012955746,0.0005870847,0.02673659,0.021528203,0.9409521,0.0000350109],"about_ca_topic_score_codex":0.0003204064,"about_ca_topic_score_gemma":0.00044472973,"teacher_disagreement_score":0.0037139442,"about_ca_system_score_codex":0.0007590146,"about_ca_system_score_gemma":0.00062260043,"threshold_uncertainty_score":0.01242435},"labels":[],"label_agreement":null},{"id":"W2112661022","doi":"10.1517/13543776.2014.1000303","title":"Therapeutic uses of furin and its inhibitors: a patent review","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Cellular transport and secretion","field":"Biochemistry, Genetics and Molecular Biology","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Furin; Context (archaeology); Clinical trial; Medicine; Drug discovery; Computational biology; Pharmacology; Bioinformatics; Biology; Biochemistry; Enzyme","score_opus":0.17319279252688577,"score_gpt":0.363310240735042,"score_spread":0.1901174482081562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112661022","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002496012,0.9954334,0.0002529037,0.00075909874,0.00032285455,0.00001818505,0.000074517535,0.0000138399455,0.0028755167],"genre_scores_gemma":[0.0012265891,0.9969838,0.00026458447,0.00037832482,0.00020228804,0.000013774975,0.00007765901,0.0000020839548,0.0008508587],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978524,0.000031051335,0.000026716914,0.000035931243,0.00009627317,0.000024764759],"domain_scores_gemma":[0.9996457,0.00018177669,0.0000645879,0.00000865171,0.000075441225,0.000023787768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005356271,0.00070844765,0.001117319,0.002375149,0.00031938654,0.0010229792,0.00079987047,0.0011050329,0.008273547],"category_scores_gemma":[0.0009083624,0.00024008368,0.00068942463,0.0020476582,0.00037600077,0.0012942695,0.00047958424,0.0014709374,0.002558121],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006621436,0.0000692132,0.00010172944,0.019601282,0.00007683212,0.00039004695,0.000061141334,0.00035342807,0.0018494992,0.005154083,0.045256604,0.92701995],"study_design_scores_gemma":[0.00001748279,0.00006987182,0.00033020522,0.00446338,0.00010262327,0.0010359935,0.000031904983,0.00006901677,0.0003952597,0.0014953316,0.9919763,0.000012712196],"about_ca_topic_score_codex":0.0007936819,"about_ca_topic_score_gemma":0.001444011,"teacher_disagreement_score":0.008273547,"about_ca_system_score_codex":0.00062226073,"about_ca_system_score_gemma":0.001138961,"threshold_uncertainty_score":0.027677774},"labels":[],"label_agreement":null},{"id":"W2117496910","doi":"10.1517/13543776.18.9.975","title":"Structural biology in the battle against BCR-Abl","year":2008,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Vertex Pharmaceuticals; Bristol-Myers Squibb; Boehringer Ingelheim","keywords":"Imatinib; Chronic myelogenous leukemia; Tyrosine kinase; Drug resistance; ABL; Tyrosine-kinase inhibitor; Drug; Cancer research; Pharmacology; Medicine; Leukemia; Biology; Cancer; Immunology; Myeloid leukemia; Internal medicine; Receptor; Genetics","score_opus":0.10270415001056933,"score_gpt":0.34708296736244654,"score_spread":0.24437881735187722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117496910","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.112783745,0.6472512,0.033282366,0.10453738,0.0031354076,0.00018804017,0.00029214178,0.00058406737,0.09794561],"genre_scores_gemma":[0.44420278,0.49868935,0.018891618,0.015330662,0.0015071273,0.00012042775,0.00027548365,0.000086455184,0.02089611],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981934,0.00004755914,0.0000069949187,0.000023122397,0.00006283012,0.000040134306],"domain_scores_gemma":[0.99987173,0.000047756894,0.000022807984,0.0000074389327,0.00002255736,0.000027710938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059454795,0.0004563235,0.00053260964,0.00043978906,0.00050902547,0.0011603207,0.0005765725,0.00124966,0.003998671],"category_scores_gemma":[0.00034304676,0.00019233623,0.00026907146,0.0005162907,0.0013150033,0.0025418678,0.00072654185,0.0018685083,0.0017873709],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049046,0.00033283522,0.00065539824,0.0029757796,0.000086806045,0.001026035,0.0005273402,0.0104791345,0.22127476,0.35476577,0.030741258,0.37664443],"study_design_scores_gemma":[0.00026258145,0.0011354954,0.0007609572,0.00038997194,0.00006930107,0.0019338162,0.00043592392,0.004270314,0.06861318,0.16603255,0.75604,0.000055969496],"about_ca_topic_score_codex":0.0003625638,"about_ca_topic_score_gemma":0.00055375026,"teacher_disagreement_score":0.003998671,"about_ca_system_score_codex":0.0011086499,"about_ca_system_score_gemma":0.0007575766,"threshold_uncertainty_score":0.013376892},"labels":[],"label_agreement":null},{"id":"W2124374772","doi":"10.1517/13543770802557740","title":"Non-antibiotic strategies for the prevention/treatment of<i>Clostridium difficile</i>infection","year":2008,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Clostridium difficile and Clostridium perfringens research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Institute for Biological Sciences","funders":"","keywords":"Clostridium difficile; Metronidazole; Medicine; Antibiotics; Vancomycin; Intensive care medicine; Enterocolitis; Diarrhea; Disease; Internal medicine; Microbiology; Bacteria; Biology; Staphylococcus aureus","score_opus":0.12955088693887748,"score_gpt":0.37628800678545005,"score_spread":0.24673711984657257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124374772","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031277634,0.88617986,0.0087398635,0.023604555,0.0024699147,0.00022025048,0.00016034173,0.000117093026,0.047230467],"genre_scores_gemma":[0.24536444,0.7094459,0.0128986025,0.008042731,0.004215197,0.00025437554,0.0003096454,0.000031724412,0.019437345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99961686,0.00010768021,0.000026647002,0.000034781762,0.00015770241,0.00005630662],"domain_scores_gemma":[0.99935013,0.00025524723,0.00015760411,0.000030260075,0.00014884406,0.000057935926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087823655,0.0003645607,0.0005025908,0.0009716951,0.0003285357,0.00085578684,0.00084804,0.0011137644,0.016278546],"category_scores_gemma":[0.0010361909,0.00006600561,0.00040245167,0.00054132723,0.00058841775,0.00096121285,0.00040956686,0.00080650393,0.0022457445],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071019743,0.0011055402,0.0014230183,0.007413933,0.00010145432,0.0021030458,0.00017102559,0.00036646612,0.034191467,0.02299866,0.03212717,0.8972881],"study_design_scores_gemma":[0.0009524551,0.004560632,0.008287109,0.004095406,0.00042790477,0.010300097,0.0006335305,0.000777363,0.040730882,0.020521123,0.9086507,0.000062793064],"about_ca_topic_score_codex":0.00029666052,"about_ca_topic_score_gemma":0.0007133228,"teacher_disagreement_score":0.016278546,"about_ca_system_score_codex":0.00048651386,"about_ca_system_score_gemma":0.00080637715,"threshold_uncertainty_score":0.054457128},"labels":[],"label_agreement":null},{"id":"W2137798595","doi":"10.1517/13543771003702432","title":"Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase","year":2010,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Steatosis; Pharmacology; Medicine; Disease; Metabolic syndrome; Diabetes mellitus; Chemistry; Bioinformatics; Biochemistry; Biology; Internal medicine; Endocrinology","score_opus":0.0652826197250013,"score_gpt":0.3566787178923051,"score_spread":0.29139609816730383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137798595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4524793,0.35856828,0.02415767,0.009220587,0.0021002593,0.0008103637,0.0009626198,0.0002917056,0.15140924],"genre_scores_gemma":[0.77053005,0.17310569,0.011413723,0.0024640514,0.0007424976,0.00020547894,0.0005145289,0.000032556603,0.040991496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999138,0.000020887035,0.000004101354,0.000013971832,0.000025785208,0.00002154447],"domain_scores_gemma":[0.99994767,0.000014354456,0.000013798623,0.0000033502781,0.0000112504285,0.000009613746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024577547,0.00027677655,0.0003600657,0.0004109596,0.00020235275,0.00032818105,0.00045778806,0.0005704736,0.007317207],"category_scores_gemma":[0.00017795424,0.000098660596,0.00022024591,0.0003497829,0.00022668258,0.0005485049,0.0002268681,0.0005244441,0.0012685044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015714891,0.00087828434,0.00048828556,0.0015455416,0.00006680226,0.0027317936,0.00037271643,0.0020315722,0.57225835,0.0274894,0.012388742,0.37817708],"study_design_scores_gemma":[0.0017455604,0.009369711,0.004747877,0.0007809496,0.00027101272,0.0059340647,0.00030737248,0.004257991,0.4425818,0.008386284,0.521509,0.00010831988],"about_ca_topic_score_codex":0.00030112208,"about_ca_topic_score_gemma":0.0008819187,"teacher_disagreement_score":0.007317207,"about_ca_system_score_codex":0.00027031134,"about_ca_system_score_gemma":0.0002024286,"threshold_uncertainty_score":0.024478495},"labels":[],"label_agreement":null},{"id":"W2156817850","doi":"10.1517/13543776.16.7.977","title":"TRPV1 antagonists: a survey of the patent literature","year":2006,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"","keywords":"TRPV1; Pharmacology; Medicine; Clinical trial; Computational biology; Business; Biology; Receptor; Internal medicine; Transient receptor potential channel","score_opus":0.12225705841958406,"score_gpt":0.3083448457455742,"score_spread":0.18608778732599013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156817850","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033183484,0.9898912,0.00041167176,0.0013211303,0.00015061753,0.000021577978,0.00020161638,0.00002408256,0.0046597146],"genre_scores_gemma":[0.0074059363,0.9900401,0.0005027557,0.0005594801,0.00027346282,0.000019085237,0.00026794043,0.0000059253757,0.0009251909],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993161,0.00008083621,0.0001101966,0.00010427854,0.00033074166,0.000057927267],"domain_scores_gemma":[0.9978555,0.0010636185,0.00049578963,0.00004311269,0.00043135043,0.0001106428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015712416,0.0007550649,0.0013399228,0.00858288,0.0004308704,0.0014299687,0.0009702741,0.0011617806,0.009219827],"category_scores_gemma":[0.0032106386,0.0002571758,0.00079513,0.007865391,0.00040537838,0.0025757954,0.0004946935,0.00082173775,0.0025796192],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032027587,0.00013703393,0.0009010887,0.012301555,0.00013305822,0.0014453487,0.00012650527,0.0004239981,0.00415455,0.002401452,0.023922665,0.95373255],"study_design_scores_gemma":[0.00013862808,0.000977273,0.009312505,0.008930205,0.0007463665,0.008914697,0.00028955712,0.00044434489,0.00372707,0.0042148377,0.9622537,0.000051012477],"about_ca_topic_score_codex":0.00068419153,"about_ca_topic_score_gemma":0.0012029272,"teacher_disagreement_score":0.009219827,"about_ca_system_score_codex":0.00091914507,"about_ca_system_score_gemma":0.00133247,"threshold_uncertainty_score":0.030843377},"labels":[],"label_agreement":null},{"id":"W2162925667","doi":"10.1517/13543776.13.7.979","title":"Epilepsy drug review: patent activity from 1999 to 2002","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Epilepsy; Drug; Anticonvulsant; Anticonvulsant drugs; Medicine; Action (physics); Pharmacology; Psychiatry","score_opus":0.10701063613566658,"score_gpt":0.3617737780236091,"score_spread":0.2547631418879425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162925667","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028034372,0.9795981,0.00030173105,0.0025649709,0.0012895565,0.000043900833,0.00053136813,0.00002983573,0.01283711],"genre_scores_gemma":[0.011788714,0.9750836,0.0007856722,0.0020328793,0.0014298066,0.00003556281,0.0007245946,0.000009119854,0.008110092],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995054,0.000069496324,0.00008138716,0.000059695132,0.00023121102,0.00005292576],"domain_scores_gemma":[0.9985538,0.00043302035,0.00043978618,0.000022620523,0.00048333223,0.00006741574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008636831,0.00060028,0.0009052318,0.004687868,0.00027083448,0.0013343679,0.00045712478,0.0009371489,0.0062365583],"category_scores_gemma":[0.0029241296,0.00015302507,0.00056425075,0.0062966323,0.00023394279,0.0014585513,0.0004216758,0.0006294759,0.0021970042],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039023944,0.00007185146,0.00040206485,0.013753109,0.00014181183,0.00065914454,0.00006880972,0.00028468063,0.0024840746,0.0021891485,0.10823724,0.87131774],"study_design_scores_gemma":[0.00006400611,0.00021014495,0.0033564211,0.0029623816,0.00036507845,0.0014833005,0.00004168617,0.00009215289,0.0011517667,0.00052792905,0.98973185,0.000013265176],"about_ca_topic_score_codex":0.0019408098,"about_ca_topic_score_gemma":0.005935668,"teacher_disagreement_score":0.0062365583,"about_ca_system_score_codex":0.0013170055,"about_ca_system_score_gemma":0.0019987177,"threshold_uncertainty_score":0.020863354},"labels":[],"label_agreement":null},{"id":"W2173701041","doi":"10.1517/13543776.2016.1115836","title":"Transglutaminase inhibitors: a patent review","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Blood properties and coagulation","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Tissue transglutaminase; Deamidation; Glutamine; Enzyme; Disease; GTP'; Cancer; Biochemistry; Pharmacology; Chemistry; Medicine; Biology; Cancer research; Amino acid; Internal medicine","score_opus":0.34857619274033974,"score_gpt":0.4178338653797347,"score_spread":0.06925767263939497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173701041","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025020094,0.99501157,0.00015564484,0.0009237844,0.00037946834,0.000016610604,0.00008722836,0.000013810749,0.003161686],"genre_scores_gemma":[0.0013451433,0.99655044,0.00017973162,0.0004727248,0.00023621018,0.000012368575,0.00009831869,0.000002023168,0.0011030837],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998098,0.000025662399,0.000023449906,0.000031055115,0.00008818443,0.000021885602],"domain_scores_gemma":[0.9997023,0.00012931986,0.000061565486,0.000006598895,0.00007786571,0.000022387332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047041522,0.00065792043,0.0010359974,0.0018743379,0.00025857505,0.0009920034,0.00073097483,0.0010642796,0.011417258],"category_scores_gemma":[0.0008942913,0.0002045621,0.0007083643,0.0019400461,0.00025860587,0.0011150388,0.0004554253,0.0012967793,0.0035881177],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007875446,0.000058443795,0.00008890334,0.019902483,0.00009170269,0.0003339699,0.00004995922,0.00022639174,0.0013488405,0.0036981625,0.0619744,0.91214794],"study_design_scores_gemma":[0.000026949368,0.00008109835,0.0003397666,0.0061908993,0.00015287293,0.0009519801,0.000033245546,0.000054358083,0.000321491,0.0013992119,0.9904373,0.000010670434],"about_ca_topic_score_codex":0.0007375916,"about_ca_topic_score_gemma":0.0014412701,"teacher_disagreement_score":0.011417258,"about_ca_system_score_codex":0.00050467474,"about_ca_system_score_gemma":0.0011484392,"threshold_uncertainty_score":0.038194597},"labels":[],"label_agreement":null},{"id":"W2179086760","doi":"10.1517/13543776.2016.1118062","title":"Evaluation of WO2015042088 A1 - a novel urea-based scaffold for TrkA inhibition","year":2015,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Nerve injury and regeneration","field":"Neuroscience","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Trk receptor; Tropomyosin receptor kinase A; Chemistry; Kinase; Pharmacology; Biochemistry; Receptor; Nerve growth factor; Biology","score_opus":0.4187022352765148,"score_gpt":0.41256677857361945,"score_spread":0.006135456702895337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2179086760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8671173,0.047861192,0.010748309,0.001861586,0.0010281643,0.0010608636,0.004467996,0.00079343095,0.06506118],"genre_scores_gemma":[0.9538014,0.02133102,0.005126844,0.0008730451,0.00009643304,0.00033229555,0.0023408504,0.0000584471,0.016039582],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999089,0.0000113019105,0.000006123997,0.000016795371,0.00003412807,0.00002276574],"domain_scores_gemma":[0.9999565,0.0000036132442,0.0000078475005,0.0000022219426,0.00001062191,0.000019225597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018562708,0.00042758638,0.0005199054,0.000474386,0.00019053483,0.00036440053,0.0003719091,0.0005021426,0.0045077894],"category_scores_gemma":[0.00019818364,0.0001415707,0.0003576698,0.0003340107,0.00013187437,0.00032288377,0.0003133866,0.000720575,0.0012111224],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001654458,0.0019474492,0.000434763,0.0029564758,0.00014464093,0.0016106811,0.00017515161,0.0048421435,0.83765507,0.004980902,0.014966247,0.12863211],"study_design_scores_gemma":[0.0024893614,0.03450868,0.008802995,0.0009156233,0.0004487267,0.0026880193,0.00029276384,0.017261924,0.69705904,0.0025009282,0.23281756,0.00021436205],"about_ca_topic_score_codex":0.00060333026,"about_ca_topic_score_gemma":0.0017292134,"teacher_disagreement_score":0.0045077894,"about_ca_system_score_codex":0.00019206096,"about_ca_system_score_gemma":0.0002762303,"threshold_uncertainty_score":0.015080035},"labels":[],"label_agreement":null},{"id":"W2466927139","doi":"10.1080/13543776.2016.1206080","title":"Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Fondation Leducq","keywords":"PCSK9; Alirocumab; Evolocumab; Kexin; Proprotein convertase; Dyslipidemia; Medicine; Pharmacology; Monoclonal antibody; Cholesterol; LDL receptor; Antibody; Internal medicine; Immunology; Lipoprotein; Disease","score_opus":0.08188793832644997,"score_gpt":0.36030734811684423,"score_spread":0.27841940979039426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2466927139","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020349649,0.9971439,0.000098038865,0.00085104565,0.0003471498,0.000006093775,0.000037904018,0.0000070579567,0.0013052672],"genre_scores_gemma":[0.0008343521,0.99767274,0.00013247653,0.00037756583,0.00026844296,0.000005035476,0.000048533446,0.0000012490509,0.0006596654],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975044,0.000034932218,0.000037049685,0.00003825794,0.00011051545,0.000028833088],"domain_scores_gemma":[0.99960357,0.00016488123,0.000082465434,0.0000071685445,0.000116874166,0.000025066105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062399404,0.0005942097,0.0009380673,0.0024609517,0.0002679438,0.0011689021,0.00053400657,0.0010061326,0.007181922],"category_scores_gemma":[0.0010052741,0.00020253262,0.0007471264,0.0024510801,0.00027108664,0.0015072117,0.000560586,0.0013563514,0.0021025874],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008085599,0.000052360112,0.00013488735,0.019438894,0.00008841042,0.00025543812,0.00007379996,0.0002254743,0.0013289936,0.003938598,0.049212895,0.9251693],"study_design_scores_gemma":[0.000029732366,0.000112345835,0.0007764707,0.008141415,0.00022334541,0.0012251638,0.00007086651,0.00009873017,0.0003737918,0.0018107569,0.98711735,0.000020077714],"about_ca_topic_score_codex":0.00086579536,"about_ca_topic_score_gemma":0.0018763436,"teacher_disagreement_score":0.007181922,"about_ca_system_score_codex":0.00065095053,"about_ca_system_score_gemma":0.0014820336,"threshold_uncertainty_score":0.024025917},"labels":[],"label_agreement":null},{"id":"W2500524559","doi":"10.1080/13543776.2016.1216545","title":"Therapeutic significance of quinolines: a patent review (2013-2015)","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Synthesis and Reactivity of Heterocycles","field":"Chemistry","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Quinoline; Pharmacophore; Antimicrobial; Broad spectrum; Combinatorial chemistry; Chemistry; Pharmacology; Medicine; Computational biology; Biology; Bioinformatics; Organic chemistry","score_opus":0.17850585215273945,"score_gpt":0.3792114764262831,"score_spread":0.20070562427354366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2500524559","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00084805576,0.9906584,0.0003852829,0.0007046736,0.0003716689,0.000035300574,0.00015769106,0.000024407449,0.0068144565],"genre_scores_gemma":[0.0044353,0.9917024,0.00039088132,0.00038127732,0.00020103747,0.000020324405,0.00015924059,0.00000390421,0.0027056613],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998456,0.000016375037,0.000017166965,0.000028827913,0.00006650302,0.000025460107],"domain_scores_gemma":[0.9997881,0.0000639375,0.000053720756,0.0000057888424,0.00006530958,0.0000230803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004276765,0.0006907584,0.000815973,0.0026270198,0.00028700373,0.0009950873,0.0006344171,0.00073961663,0.01005551],"category_scores_gemma":[0.00062121963,0.00022860801,0.00062524894,0.0023783161,0.0002849784,0.0011059237,0.0004958797,0.001189212,0.0032607445],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008488065,0.0000709176,0.00014418994,0.016048409,0.00007114623,0.00049688877,0.00006806862,0.0003910107,0.0039424133,0.0046930704,0.029897217,0.9440918],"study_design_scores_gemma":[0.000024438927,0.00013466648,0.00081557425,0.0034080388,0.00013800642,0.0013906416,0.000048086054,0.000101316145,0.0012425276,0.0012019324,0.99147826,0.000016501861],"about_ca_topic_score_codex":0.00090268144,"about_ca_topic_score_gemma":0.0020846892,"teacher_disagreement_score":0.01005551,"about_ca_system_score_codex":0.0006434078,"about_ca_system_score_gemma":0.0011375796,"threshold_uncertainty_score":0.033639014},"labels":[],"label_agreement":null},{"id":"W2590195415","doi":"10.1080/13543776.2017.1297796","title":"Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 –<i>Part I</i>","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Nerve injury and regeneration","field":"Neuroscience","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Trk receptor; Tropomyosin receptor kinase A; Kinase; Context (archaeology); Biology; Receptor; Neurotrophin; Cell biology; Biochemistry","score_opus":0.40899024812389073,"score_gpt":0.4358830275645397,"score_spread":0.026892779440648995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590195415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00053084287,0.9885262,0.00036003764,0.001261557,0.0010325172,0.00004587543,0.00037201314,0.00004237054,0.007828536],"genre_scores_gemma":[0.0019076138,0.99280083,0.00037803242,0.0007519617,0.00039316688,0.000026359385,0.00037962527,0.0000059393947,0.0033563809],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998118,0.000020943504,0.000026260446,0.000032575237,0.00008012762,0.000028369088],"domain_scores_gemma":[0.9997689,0.0000708192,0.00005979966,0.0000058255596,0.000073565854,0.00002105995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039428932,0.0007720017,0.00096132094,0.0023551704,0.00026371435,0.0010495711,0.0007601191,0.00081537606,0.014448098],"category_scores_gemma":[0.00073192565,0.00022880534,0.00077981735,0.0022175172,0.00025417263,0.0013846832,0.00053428987,0.0014079323,0.0051660766],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101160884,0.000064222826,0.00009048074,0.02267423,0.00008065679,0.00030397985,0.000063141764,0.00026689834,0.0033993225,0.0036941518,0.0996569,0.8696049],"study_design_scores_gemma":[0.000018971208,0.000082133505,0.00038132226,0.0028762862,0.00010901341,0.0007351332,0.000024584024,0.00005472388,0.0004856002,0.0007286708,0.99449074,0.000012822785],"about_ca_topic_score_codex":0.0009862685,"about_ca_topic_score_gemma":0.0026116674,"teacher_disagreement_score":0.014448098,"about_ca_system_score_codex":0.00067282136,"about_ca_system_score_gemma":0.0013748457,"threshold_uncertainty_score":0.048333704},"labels":[],"label_agreement":null},{"id":"W2590797524","doi":"10.1080/13543776.2017.1296950","title":"Patent disclosure requirements for therapeutic antibody patents","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Antibody; Pharmacology; Medicine; Immunology","score_opus":0.6197336892953145,"score_gpt":0.48238085560467564,"score_spread":0.13735283369063883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590797524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021621718,0.8701632,0.0047743022,0.027505986,0.0017771636,0.00025942692,0.0018564487,0.00008168393,0.09141958],"genre_scores_gemma":[0.07153792,0.8857454,0.0056363847,0.014564889,0.0040972363,0.0005147375,0.002645612,0.00003577533,0.015222019],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9879881,0.0032691404,0.0015889757,0.0008256047,0.005843628,0.0004845192],"domain_scores_gemma":[0.9597558,0.028991323,0.0061497795,0.00076640095,0.0040173545,0.0003194259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009971257,0.00052729744,0.001106944,0.0032281284,0.00058179215,0.0028353904,0.0018175426,0.005046458,0.022604693],"category_scores_gemma":[0.03964463,0.0002620144,0.0012894707,0.0026743053,0.0016139975,0.0028001494,0.0011237063,0.002870592,0.003494859],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013016447,0.000055894325,0.000698982,0.02218823,0.00013480961,0.00065019645,0.00022790307,0.0009870452,0.001228761,0.1655979,0.11257071,0.6955294],"study_design_scores_gemma":[0.000049122944,0.00008771496,0.0021021608,0.016326735,0.00014606191,0.0015753851,0.000081161226,0.00021153511,0.00087672396,0.023704642,0.9548077,0.00003107881],"about_ca_topic_score_codex":0.0025826576,"about_ca_topic_score_gemma":0.0017954472,"teacher_disagreement_score":0.022604693,"about_ca_system_score_codex":0.0020160722,"about_ca_system_score_gemma":0.0062697716,"threshold_uncertainty_score":0.07562029},"labels":[],"label_agreement":null},{"id":"W2762459231","doi":"10.1080/13543776.2018.1388780","title":"Bill C-30: who wins and who loses in Canada’s pharmaceutical patent battles?","year":2017,"lang":"en","type":"editorial","venue":"Expert Opinion on Therapeutic Patents","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Business; Patent analysis; Patent troll; Patent law; Law; Political science; Computer science; Intellectual property","score_opus":0.14818294676430427,"score_gpt":0.340395631864411,"score_spread":0.19221268510010675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762459231","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006315545,0.012419913,0.00009010532,0.45138875,0.52971005,0.00004110642,0.00022460026,0.00004392681,0.006018364],"genre_scores_gemma":[0.0014828764,0.009604037,0.00020142457,0.31544816,0.6483722,0.00006777769,0.00010284199,0.00007325434,0.024647491],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9799137,0.0022469657,0.0019228713,0.0017378015,0.011462607,0.0027160414],"domain_scores_gemma":[0.94376683,0.024091402,0.0027347717,0.0011160561,0.02240325,0.005887659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017559888,0.00318886,0.0043357713,0.0056743966,0.010147448,0.016163614,0.007937679,0.08582657,0.014934069],"category_scores_gemma":[0.07173857,0.0017391151,0.0033243771,0.0044033495,0.009088782,0.006452271,0.0026861683,0.055466153,0.007125523],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005040503,0.0000031761326,0.000012487554,0.000035807632,0.000004156102,0.00002879107,0.000014063598,0.0000069128423,0.0000059087247,0.00040768276,0.99843067,0.0010453343],"study_design_scores_gemma":[0.00004951619,0.0000075266107,0.00029037934,0.00065794715,0.00004600809,0.00006429541,0.00014075763,0.0000859173,0.00005103707,0.001919576,0.9966479,0.000039118342],"about_ca_topic_score_codex":0.1993058,"about_ca_topic_score_gemma":0.39482814,"teacher_disagreement_score":0.9681714,"about_ca_system_score_codex":0.03182857,"about_ca_system_score_gemma":0.05841027,"threshold_uncertainty_score":0.39629143},"labels":[],"label_agreement":null},{"id":"W3081954160","doi":"10.1080/13543776.2020.1817390","title":"Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract – A review of patent literature","year":2020,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Liver physiology and pathology","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Proteases; TMPRSS2; Respiratory tract; Transmembrane protein; Serine; Biology; Medicine; Pharmacology; Respiratory system; Immunology; Enzyme; Receptor; Coronavirus disease 2019 (COVID-19); Biochemistry; Pathology; Disease; Internal medicine; Infectious disease (medical specialty)","score_opus":0.15084764434932343,"score_gpt":0.3814635435339384,"score_spread":0.23061589918461498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081954160","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007476216,0.99167174,0.00053022854,0.001883027,0.0007876008,0.000030686555,0.00016801116,0.000030386049,0.0041506],"genre_scores_gemma":[0.002946752,0.99362355,0.00032319615,0.0008440247,0.0005300242,0.000025490921,0.00016958905,0.000004058623,0.0015333906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998203,0.000026791413,0.00001764481,0.000030720224,0.0000758696,0.000028628747],"domain_scores_gemma":[0.9997229,0.00010930211,0.00006135218,0.0000052960477,0.00008020076,0.000020878368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005410554,0.0005401789,0.00084786507,0.0013847834,0.00017214607,0.00084893213,0.0006246361,0.00081776606,0.008748208],"category_scores_gemma":[0.0006255413,0.00014306097,0.0006399076,0.0011740514,0.00022542817,0.00097444904,0.0003565061,0.0011189971,0.0029689695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016912445,0.00008108778,0.000130862,0.016961802,0.00012703711,0.0004077694,0.000058108883,0.00044180648,0.0035213002,0.0037675335,0.062397227,0.91193634],"study_design_scores_gemma":[0.00007166671,0.00024910874,0.00064002565,0.0054589612,0.00024372902,0.0010235909,0.000048936352,0.00019600058,0.00088229455,0.0023855716,0.9887793,0.000020799735],"about_ca_topic_score_codex":0.0004348833,"about_ca_topic_score_gemma":0.00097641733,"teacher_disagreement_score":0.008748208,"about_ca_system_score_codex":0.00038593923,"about_ca_system_score_gemma":0.00072075595,"threshold_uncertainty_score":0.029265642},"labels":[],"label_agreement":null},{"id":"W4231919180","doi":"10.1080/13543776.2017.1297797","title":"Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – <i>Part II</i>","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Signaling Pathways in Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Trk receptor; Tropomyosin receptor kinase A; Drug development; Medicine; Pharmacology; Cancer research; Internal medicine; Drug; Receptor; Neurotrophin","score_opus":0.22703980821993844,"score_gpt":0.40521853145020315,"score_spread":0.1781787232302647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231919180","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00061387726,0.9865173,0.0004471196,0.0015954212,0.0012987206,0.00005051338,0.00039174326,0.00004912041,0.009036187],"genre_scores_gemma":[0.0021923506,0.9911724,0.00043912252,0.0009423847,0.00046720775,0.000028841343,0.00041853817,0.000007060505,0.004332162],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982315,0.000019757255,0.00002291567,0.00003040089,0.00007586525,0.000027895188],"domain_scores_gemma":[0.9997967,0.000059506176,0.000051721214,0.0000052832565,0.00006627412,0.000020601216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038427868,0.00074711785,0.00089474686,0.0020608853,0.00024736114,0.0010249644,0.00073064957,0.00079656823,0.014345719],"category_scores_gemma":[0.0006686667,0.00023093435,0.00073451165,0.0019595695,0.00024699798,0.0013518713,0.0005153315,0.0014548219,0.0053804554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010037288,0.00006483311,0.000083172374,0.017911192,0.000073348,0.0003053169,0.000057040135,0.00028503154,0.0037783422,0.003914504,0.11019164,0.8632352],"study_design_scores_gemma":[0.000018939034,0.00007837294,0.0003180592,0.002058897,0.00008536935,0.0007046966,0.000020288408,0.00005500522,0.0004934957,0.0006926061,0.9954625,0.000011714694],"about_ca_topic_score_codex":0.0008883042,"about_ca_topic_score_gemma":0.002408788,"teacher_disagreement_score":0.014345719,"about_ca_system_score_codex":0.0006828929,"about_ca_system_score_gemma":0.001248154,"threshold_uncertainty_score":0.047991157},"labels":[],"label_agreement":null},{"id":"W4235008009","doi":"10.1517/eotp.13.10.1491.22914","title":"Therapeutic patents for the treatment of premenstrual syndrome and premenstrual dysphoric disorder: historical perspectives and future directions","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Menstrual Health and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Premenstrual dysphoric disorder; Etiology; Serotonergic; Medicine; Psychiatry; Physiology; Psychology; Hormone; Internal medicine; Serotonin; Menstrual cycle; Receptor","score_opus":0.058909408830325,"score_gpt":0.33067366242737745,"score_spread":0.2717642535970525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235008009","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028027473,0.94828933,0.0022559485,0.019425325,0.0011824187,0.000037593818,0.000060904043,0.00004742764,0.025898213],"genre_scores_gemma":[0.030098865,0.94562554,0.004509737,0.007962425,0.0041181324,0.00008611527,0.000089012894,0.000018279427,0.007491842],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9995666,0.00013863319,0.00003813318,0.00006192898,0.00012883409,0.000065876295],"domain_scores_gemma":[0.9985343,0.0009275617,0.00017986663,0.00004628141,0.0002208944,0.00009103417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018581677,0.0005813922,0.00077824795,0.001678746,0.00063207664,0.001880261,0.0007934425,0.0026692702,0.012158584],"category_scores_gemma":[0.0019438214,0.00018845736,0.0005304132,0.0013820344,0.0011452842,0.0036235165,0.0006129865,0.0019813445,0.0019803424],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003460328,0.0002761744,0.0004982468,0.0027260906,0.00004603073,0.002072709,0.00022116484,0.0006942709,0.0038750197,0.059695385,0.040957045,0.8885918],"study_design_scores_gemma":[0.00020043695,0.0007868332,0.0009522498,0.0019135213,0.00008419237,0.005555913,0.0003254994,0.0005595516,0.0020419355,0.03325181,0.95428956,0.00003857524],"about_ca_topic_score_codex":0.00056329696,"about_ca_topic_score_gemma":0.0012598808,"teacher_disagreement_score":0.012158584,"about_ca_system_score_codex":0.0011704982,"about_ca_system_score_gemma":0.00091270846,"threshold_uncertainty_score":0.040674448},"labels":[],"label_agreement":null},{"id":"W4256674571","doi":"10.1517/eotp.13.7.979.22985","title":"Epilepsy drug review: patent activity from 1999 to 2002","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Drug; Epilepsy; Pharmacology; Drug development; Medicine; Business; Psychiatry","score_opus":0.17062245208788937,"score_gpt":0.33226603316605974,"score_spread":0.16164358107817037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256674571","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024591503,0.9830961,0.00020796982,0.0032683723,0.0008431852,0.000030735668,0.00094268407,0.000019559244,0.009132229],"genre_scores_gemma":[0.012723585,0.97939694,0.00046270288,0.0015084024,0.0010561966,0.000025351765,0.00071525667,0.000005941732,0.0041057663],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999186,0.00014046514,0.0001373355,0.00009756637,0.00036569335,0.00007297613],"domain_scores_gemma":[0.9959494,0.0014488896,0.0012950422,0.000053901564,0.0011381698,0.00011465885],"candidate_categories":["bibliometrics"],"consensus_categories":[],"category_scores_codex":[0.0015082152,0.00049443473,0.00094191666,0.006702876,0.00023096564,0.0015246563,0.0004223305,0.0009140225,0.005199338],"category_scores_gemma":[0.006555713,0.00017800345,0.00063632766,0.012734602,0.0002510455,0.0013557012,0.00036990742,0.00051411893,0.0014011647],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049525965,0.00006418216,0.00097637094,0.023229051,0.0002886428,0.0004252454,0.00007159204,0.0006355737,0.0009225125,0.0045467373,0.1631273,0.8052175],"study_design_scores_gemma":[0.00007324914,0.00015168964,0.008658006,0.005916786,0.00058138825,0.0008130299,0.000048347407,0.00015675575,0.0005357859,0.0008094668,0.98224163,0.000013715791],"about_ca_topic_score_codex":0.0037984846,"about_ca_topic_score_gemma":0.010158384,"teacher_disagreement_score":0.9932971,"about_ca_system_score_codex":0.0020920418,"about_ca_system_score_gemma":0.0033363856,"threshold_uncertainty_score":0.01739353},"labels":[],"label_agreement":null},{"id":"W4386945206","doi":"10.1080/13543776.2023.2262136","title":"Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TRIUMF; University of British Columbia; University of Alberta","funders":"","keywords":"Trk receptor; Medicine; Precision medicine; Pharmacology; Bioinformatics; Cancer research; Computational biology; Biology; Receptor; Internal medicine; Neurotrophin; Pathology","score_opus":0.11039378927360463,"score_gpt":0.3584458892396905,"score_spread":0.24805209996608588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386945206","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007086503,0.97809005,0.00046533628,0.003003828,0.00201637,0.00005547027,0.00043232355,0.000065320695,0.015162561],"genre_scores_gemma":[0.0027317444,0.9869006,0.00045276896,0.0019646513,0.00088780513,0.000037094844,0.0004929149,0.000009665645,0.0065227216],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999765,0.000032100157,0.000022384507,0.00002837877,0.000112681875,0.00003947219],"domain_scores_gemma":[0.9996408,0.00012376801,0.00007165685,0.000007797941,0.00011802663,0.00003801401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063615,0.0007681282,0.00082149624,0.002226264,0.00023214835,0.0011858755,0.0007996141,0.0011780108,0.01927953],"category_scores_gemma":[0.00096966187,0.00018887884,0.0009245661,0.0021031017,0.00024696477,0.0013324667,0.0005223958,0.0015427866,0.0059624054],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010467669,0.00005895813,0.0000868586,0.0107504185,0.000060325085,0.0002972566,0.000035318397,0.0002576337,0.0018124057,0.003612386,0.13278748,0.85013634],"study_design_scores_gemma":[0.000030059642,0.00007166399,0.00029289073,0.002422625,0.00008287181,0.0005264697,0.000014139416,0.000056730743,0.000244209,0.00079930876,0.9954516,0.000007425489],"about_ca_topic_score_codex":0.0010454033,"about_ca_topic_score_gemma":0.0024179607,"teacher_disagreement_score":0.01927953,"about_ca_system_score_codex":0.00078642427,"about_ca_system_score_gemma":0.001367206,"threshold_uncertainty_score":0.06449646},"labels":[],"label_agreement":null},{"id":"W4398778278","doi":"10.1080/13543776.2024.2358818","title":"Type II &amp; III inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TRIUMF; University of Alberta; University of British Columbia","funders":"","keywords":"Trk receptor; Tropomyosin; Receptor; Tropomyosin receptor kinase A; Chemistry; Tropomyosin receptor kinase C; Kinase; Biochemistry; Pharmacology; Cell biology; Biology; Platelet-derived growth factor receptor; Neurotrophin","score_opus":0.039680297802238126,"score_gpt":0.29998558509465406,"score_spread":0.2603052872924159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398778278","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005814327,0.8138617,0.003894047,0.04050213,0.01856436,0.00036856372,0.0034349987,0.00053582917,0.113023974],"genre_scores_gemma":[0.02108198,0.88418144,0.0031598771,0.01866883,0.007787176,0.00022575022,0.0038491513,0.00009000197,0.06095579],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996444,0.000045043835,0.00002397385,0.000038495637,0.00017006435,0.00007802421],"domain_scores_gemma":[0.99953294,0.000103850536,0.00009163493,0.000013822238,0.00017876024,0.000079056124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000878465,0.0006418998,0.00071498466,0.001280865,0.0002918285,0.001607393,0.0008394399,0.0017298755,0.030196162],"category_scores_gemma":[0.0011779061,0.0001841331,0.0009555238,0.0011995329,0.00030610268,0.0017165696,0.0006211418,0.0021754755,0.012969966],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018508709,0.000097525015,0.00016604048,0.0028455674,0.000054900323,0.00050027657,0.00004858248,0.00026372317,0.0053008953,0.0055289534,0.30587173,0.67913675],"study_design_scores_gemma":[0.00004362069,0.00012580736,0.00028727314,0.0006564689,0.00004755173,0.00053574424,0.000013147026,0.00008449425,0.00069279864,0.0010804512,0.99642354,0.000009051991],"about_ca_topic_score_codex":0.0008655644,"about_ca_topic_score_gemma":0.0021244222,"teacher_disagreement_score":0.030196162,"about_ca_system_score_codex":0.000910341,"about_ca_system_score_gemma":0.0013705309,"threshold_uncertainty_score":0.10101622},"labels":[],"label_agreement":null},{"id":"W4402118985","doi":"10.1080/13543776.2024.2400175","title":"Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Xenon Pharmaceuticals (Canada)","funders":"","keywords":"Drug; Drug discovery; Covalent bond; Pharmacology; Business; Chemistry; Combinatorial chemistry; Medicine; Biochemistry; Organic chemistry","score_opus":0.11110982289387422,"score_gpt":0.3708849694896212,"score_spread":0.25977514659574696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402118985","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3022879,0.55127156,0.012629439,0.02263086,0.00062805373,0.0005362811,0.028781254,0.00073064555,0.08050402],"genre_scores_gemma":[0.66023874,0.29255095,0.01251281,0.004381931,0.00089997466,0.00024600208,0.02034704,0.00016969425,0.008652815],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99776757,0.00028202284,0.00020580798,0.00036054588,0.0011722593,0.00021180263],"domain_scores_gemma":[0.9908408,0.0036570684,0.0025254183,0.00014716516,0.0024811148,0.00034842847],"candidate_categories":["bibliometrics"],"consensus_categories":[],"category_scores_codex":[0.0038722204,0.0005382285,0.0007605503,0.009985997,0.00033490124,0.0036916882,0.0005300127,0.0006962463,0.006266778],"category_scores_gemma":[0.006541192,0.00017644037,0.0012062633,0.013988946,0.00035584497,0.0030753813,0.0006097264,0.0007277646,0.0014164472],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073694694,0.000155261,0.04367272,0.007925998,0.0006831503,0.00077209796,0.00034092675,0.0027636131,0.010515103,0.017953241,0.045259856,0.86922115],"study_design_scores_gemma":[0.000109694076,0.002104974,0.23212686,0.0063352166,0.0021189174,0.0040233843,0.0016157812,0.010523569,0.011909889,0.016635424,0.7123148,0.0001814522],"about_ca_topic_score_codex":0.001717199,"about_ca_topic_score_gemma":0.0031227549,"teacher_disagreement_score":0.990014,"about_ca_system_score_codex":0.00213934,"about_ca_system_score_gemma":0.002155732,"threshold_uncertainty_score":0.020964444},"labels":[],"label_agreement":null},{"id":"W4403781693","doi":"10.1080/13543776.2024.2423023","title":"Ectonucleotidase inhibitors: an updated patent review (2017–2023)","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Chemistry; Pharmacology; Medicine","score_opus":0.1443363722778405,"score_gpt":0.3912386502507594,"score_spread":0.2469022779729189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403781693","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017732505,0.9689061,0.0009860161,0.0028681557,0.00287574,0.000098591874,0.0011157778,0.0001111298,0.021265136],"genre_scores_gemma":[0.00662819,0.97380733,0.00084689585,0.0022737759,0.001130558,0.00007004717,0.0014674889,0.000018178916,0.013757644],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979335,0.000023408184,0.000019553867,0.00003307253,0.00009201781,0.0000386733],"domain_scores_gemma":[0.9998252,0.000043063163,0.00003884486,0.000004808056,0.000066478635,0.00002167352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040965437,0.0006536128,0.0008759024,0.0013880235,0.00023002963,0.001085888,0.00063454045,0.001026499,0.027249157],"category_scores_gemma":[0.00066109514,0.00019582083,0.00079437386,0.0013537626,0.00018810586,0.0010535462,0.00044828825,0.001476518,0.008883144],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001923132,0.00009952739,0.00013448384,0.013250845,0.00012414731,0.00051297114,0.00006119361,0.00036038476,0.0057966737,0.0048642554,0.13970599,0.8348971],"study_design_scores_gemma":[0.000044345506,0.00015483891,0.00040864217,0.0013002063,0.00012338631,0.0008176543,0.000017586546,0.000066569606,0.0007931049,0.00083964004,0.995419,0.000015079082],"about_ca_topic_score_codex":0.00071646215,"about_ca_topic_score_gemma":0.0015510197,"teacher_disagreement_score":0.027249157,"about_ca_system_score_codex":0.0004971464,"about_ca_system_score_gemma":0.0010038936,"threshold_uncertainty_score":0.091157496},"labels":[],"label_agreement":null},{"id":"W4412046485","doi":"10.1080/13543776.2025.2529217","title":"Recent advances in tropomyosin receptor kinase (TRK) inhibitors: a 2023–2024 patent landscape review","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of British Columbia; McMaster University","funders":"","keywords":"Trk receptor; Kinase; Receptor; Pharmacology; Medicine; Chemistry; Internal medicine; Biochemistry","score_opus":0.11193860631188104,"score_gpt":0.39808832094260943,"score_spread":0.28614971463072836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412046485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031387905,0.9935917,0.00020325613,0.0015145579,0.00045792994,0.000021062304,0.00012476486,0.000018466953,0.0037543105],"genre_scores_gemma":[0.0014363057,0.9960283,0.00022116507,0.0007241623,0.0003019718,0.000013839951,0.00011548609,0.0000030681783,0.001155652],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996779,0.000051136798,0.000040026804,0.000046910285,0.00014043636,0.000043674518],"domain_scores_gemma":[0.9993011,0.00033210908,0.000116997464,0.000011113046,0.000199375,0.000039232207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008353549,0.00074922293,0.0009874349,0.0030742588,0.00026389092,0.0013737809,0.00071909325,0.0011848605,0.013573854],"category_scores_gemma":[0.0014347682,0.00022227663,0.0010190842,0.0029633117,0.0002716263,0.0016193952,0.0005597467,0.0012749947,0.0029550816],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008733327,0.00005181668,0.00012184873,0.027647981,0.000100239304,0.00032547177,0.00007166069,0.00038676613,0.0014613323,0.0052918456,0.06001567,0.9044381],"study_design_scores_gemma":[0.000024283787,0.00009815388,0.0004322867,0.007994084,0.00017538754,0.0007000437,0.000047312406,0.00009191301,0.00027870203,0.0016703816,0.9884744,0.0000129247255],"about_ca_topic_score_codex":0.0009816618,"about_ca_topic_score_gemma":0.002290696,"teacher_disagreement_score":0.013573854,"about_ca_system_score_codex":0.0008418615,"about_ca_system_score_gemma":0.0018018357,"threshold_uncertainty_score":0.045409083},"labels":[],"label_agreement":null},{"id":"W4413414271","doi":"10.1080/13543776.2025.2548586","title":"Implementation and outcomes of China’s drug patent linkage system: lessons from international experience","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Intellectual Property and Patents","field":"Business, Management and Accounting","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Drug; Linkage (software); China; Pharmacology; Medicine; Process management; Public relations; Political science; Biology; Gene; Genetics","score_opus":0.26169260884227696,"score_gpt":0.38222949783615956,"score_spread":0.1205368889938826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413414271","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24374695,0.65197337,0.0011655163,0.02137025,0.00060612865,0.0005306587,0.0012269039,0.00005793171,0.079322346],"genre_scores_gemma":[0.66924083,0.3238055,0.0010390051,0.002091098,0.00022280702,0.000107486776,0.0005173872,0.000014363479,0.0029614568],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955462,0.001640676,0.0004750762,0.00027427313,0.0016974568,0.0003663141],"domain_scores_gemma":[0.99425405,0.002597746,0.0008931404,0.0001663497,0.0018701353,0.00021860396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010134319,0.00024984518,0.0005174083,0.0016510378,0.00048489877,0.0019432766,0.00070817664,0.0006969984,0.002482643],"category_scores_gemma":[0.012905144,0.00009913789,0.00040727697,0.0039660716,0.00077118515,0.0015862203,0.00072014524,0.00077166077,0.00017676402],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026616207,0.00020466858,0.022899684,0.017166892,0.00026950016,0.0012665531,0.0060010334,0.0012287578,0.0013855776,0.031473543,0.018983908,0.89885384],"study_design_scores_gemma":[0.00022695758,0.0021128976,0.25651494,0.021221317,0.0011488852,0.0022334873,0.0106326835,0.0014555932,0.005427785,0.0045116926,0.6943575,0.00015628569],"about_ca_topic_score_codex":0.027251786,"about_ca_topic_score_gemma":0.03086211,"teacher_disagreement_score":0.027251786,"about_ca_system_score_codex":0.0043168925,"about_ca_system_score_gemma":0.01500884,"threshold_uncertainty_score":0.054186285},"labels":[],"label_agreement":null},{"id":"W4417222214","doi":"10.1080/13543776.2025.2602703","title":"Tricyclic boronic acids as broad-spectrum serine and metallo-β-lactamase inhibitors with <i>in vitro</i> activity against <i>Acinetobacter baumannii</i> : a patent evaluation (US 2025/0223303)","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Synthesis of β-Lactam Compounds","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University","keywords":"Scope (computer science); Context (archaeology); Serine; Tricyclic; Enzyme; Boronic acid","score_opus":0.07328824272488464,"score_gpt":0.3353653821753039,"score_spread":0.26207713945041927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417222214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.053701043,0.8485493,0.00685622,0.0152628785,0.003857737,0.00020457788,0.0017964907,0.00025098608,0.06952086],"genre_scores_gemma":[0.26373404,0.68268704,0.003937123,0.009287132,0.0026451228,0.00010344299,0.0017889878,0.00003409158,0.035782974],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998325,0.00003053297,0.000009008674,0.000027877208,0.00006944618,0.00003054765],"domain_scores_gemma":[0.99987817,0.000024273133,0.000036375448,0.000003524827,0.000043259366,0.000014358058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038210463,0.00028219167,0.00029215866,0.00028489224,0.00008619836,0.00056565995,0.00048235155,0.0007545412,0.009270304],"category_scores_gemma":[0.00040828748,0.00008278907,0.00027276896,0.00027984413,0.00018245965,0.0004433127,0.00020137728,0.0005371939,0.0022742373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013428234,0.00024396824,0.000785554,0.009277241,0.00017495522,0.0016133655,0.00011812698,0.002070039,0.10580212,0.00865285,0.11507325,0.75484574],"study_design_scores_gemma":[0.00041554333,0.002142107,0.00174427,0.0019068227,0.0002312205,0.0036472369,0.00019055484,0.0021686323,0.06550014,0.0034137063,0.9185678,0.00007201076],"about_ca_topic_score_codex":0.00048556918,"about_ca_topic_score_gemma":0.001034764,"teacher_disagreement_score":0.009270304,"about_ca_system_score_codex":0.00038914525,"about_ca_system_score_gemma":0.00030493,"threshold_uncertainty_score":0.031012297},"labels":[],"label_agreement":null}]}